

Cite this: *Chem. Sci.*, 2024, 15, 10918

All publication charges for this article have been paid for by the Royal Society of Chemistry

Received 27th February 2024

Accepted 29th May 2024

DOI: 10.1039/d4sc01368a

rsc.li/chemical-science

## $\alpha$ -Amino bicycloalkylation through organophotoredox catalysis†

Jeremy Nugent,<sup>‡a</sup> Adrián López-Francés,<sup>ID ‡b</sup> Alistair J. Sterling,<sup>‡a</sup> Min Yi Tay,<sup>a</sup> Nils Frank,<sup>a</sup> James J. Mousseau,<sup>c</sup> Fernanda Duarte,<sup>ID \*a</sup> and Edward A. Anderson,<sup>ID \*a</sup>

Bridged bicycloalkanes such as bicyclo[1.1.1]pentanes (BCPs) and bicyclo[3.1.1]heptanes (BCHePs) are important motifs in contemporary drug design due to their potential to act as bioisosteres of disubstituted benzene rings, often resulting in compounds with improved physicochemical and pharmacokinetic properties. Access to such motifs with proximal nitrogen atoms (*i.e.*  $\alpha$ -amino/amido bicycloalkanes) is highly desirable for drug discovery applications, but their synthesis is challenging. Here we report an approach to  $\alpha$ -amino BCPs and BCHePs through the visible-light enabled addition of  $\alpha$ -amino radicals to the interbridgehead C–C bonds of [1.1.1] and [3.1.1]propellane respectively. The reaction proceeds under exceptionally mild conditions and displays broad substrate scope, providing access to an array of medically-relevant BCP and BCHeP products. Experimental and computational mechanistic studies provide evidence for a radical chain pathway which depends critically on the stability of the  $\alpha$ -amino radical, as well as effective catalyst turnover.

## Introduction

$sp^3$ -Rich ‘cage’ hydrocarbons are becoming increasingly commonplace in contemporary drug design due to their beneficial physicochemical properties compared to ‘classic’ drug functionalities such as benzene rings.<sup>1–3</sup> Compounds featuring these rigid scaffolds often exhibit improved pharmacological profiles compared to their parent structure, such as resistance to metabolism, while increasing three-dimensionality.<sup>4–7</sup> For example, 1,3-disubstituted BCPs are often deployed as bioisosteres for *para*-substituted arenes and alkynes, as they retain the specific positioning of substituents (180°),<sup>8–12</sup> while their use as general property-enhancing motifs is also emerging.<sup>13–15</sup> Similarly, monosubstituted BCPs are desirable as surrogates for phenyl and *t*-butyl groups (Fig. 1a).<sup>16,17</sup> Recently, we reported the generation of the homologous bicyclo[3.1.1]heptanes (BCHePs), and described their use as potential bioisosteres of *meta*-




Fig. 1 (a) Examples of monosubstituted BCPs in drug discovery. (b) Synthesis of mono-substituted BCPs from [1.1.1]propellane. (c) This work: synthesis of  $\alpha$ -amino BCPs and BCHePs by addition of  $\alpha$ -amino radicals to propellanes.

<sup>a</sup>Department of Chemistry, Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford, OX1 3TA, UK. E-mail: fernandaduarte@chem.ox.ac.uk; edward.anderson@chem.ox.ac.uk

<sup>b</sup>Department of Organic Chemistry I, Faculty of Pharmacy and Lascaray Research Center, University of the Basque Country, UPV/EHU, Paseo de la Universidad 7, 01006, Vitoria-Gasteiz, Spain

<sup>c</sup>Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, USA

† Electronic supplementary information (ESI) available: Experimental procedures, computational details, copies of <sup>1</sup>H and <sup>13</sup>C NMR spectra. See DOI: <https://doi.org/10.1039/d4sc01368a>

‡ These authors contributed equally.



substituted arenes, in which the bridgehead substituent vectors faithfully replicate those of the aromatic ring ( $\sim 120^\circ$ ).<sup>18</sup>

These important rigid scaffolds are typically derived from [n.1.1]propellanes, which are convenient building blocks due to the diversity of functionality that can be introduced during ring-opening of the central C–C bond, especially using radicals<sup>19–32</sup> and, for [1.1.1]propellane, anions.<sup>33–38</sup> In the case of mono-substituted BCPs, synthetic approaches are most commonly anionic in nature (Fig. 1b); examples include the addition to **1** of aryl Grignard reagents,<sup>12</sup> turbo amides,<sup>34,35</sup> enolates,<sup>39</sup> dithiane<sup>36</sup> and azaallyl<sup>37,38</sup> anions. While these methods provide ready access to valuable BCP building blocks, they are moisture- and/or air-sensitive and thus display limited functional group tolerance. Single electron strategies also enable the synthesis of monosubstituted BCPs, but have generally been limited to electron-deficient or thiyl (and related) radicals.<sup>24–28</sup>


$\alpha$ -Amino BCPs are highly desirable in medicinal chemistry as analogues of benzylamines – motifs found in many pharmaceuticals.<sup>40</sup> The synthesis of these potentially valuable compounds has been mostly overlooked, with the few reported examples requiring lengthy reaction sequences, pyrophoric/strongly basic reagents, or being limited to  $1^\circ$  amines.<sup>37,41–44</sup> As such, the synthesis of  $\alpha$ -amino BCPs or BCHePs directly from [1.1.1]propellane **1** and [3.1.1]propellane **2** respectively

represents an attractive yet unexplored route – especially in the latter case, as anionic additions to **2** are unfeasible.<sup>37</sup> While these propellanes are well-established to react efficiently with electrophilic radicals,<sup>13,25,45,46</sup> the addition of nucleophilic radicals is less studied.<sup>47</sup> We questioned whether the direct addition of nucleophilic  $\alpha$ -amino radicals (generated *via* photoredox-catalysed oxidation of simple *N,N*-dialkylanilines)<sup>48–58</sup> to propellanes **1** or **2** could generate these useful  $\alpha$ -amino bicycloalkanes in a single step. Here we report the successful development of this methodology, which represents the first examples of the ring-opening of [1.1.1] and [3.1.1]propellanes using  $\alpha$ -amino radicals. We complement the development of this chemistry with a detailed mechanistic study that investigates the role of each reaction component, including the source of the BCP/BCHeP bridgehead hydrogen atom.

## Results and discussion

We began our investigations with the reaction of [1.1.1]propellane (**1**) with *N*-phenylpyrrolidine (**3a**, 5 equiv.) in the presence of the moderately oxidising photocatalyst Ir[(dF(CF<sub>3</sub>)ppy)<sub>2</sub>dtbbpy]PF<sub>6</sub> ([Ir]**1**,  $E^\circ(\text{Ir(III)}^*/\text{Ir(II)}) = +1.21 \text{ V vs. SCE}$ )<sup>59</sup> in MeCN (0.5 M) under 455 nm blue LED irradiation. We were pleased to find that the desired BCP product **4a** was delivered in



Table 1 Optimisation of the addition of  $\alpha$ -amino radicals to [1.1.1]propellane



| Entry     | PC                             | Solvent | Amine eq. | Light source       | Time (h)  | Yield <sup>a</sup> (%) ( <b>4a</b> : <b>5a</b> ) |
|-----------|--------------------------------|---------|-----------|--------------------|-----------|--|
| 1         | [Ir] <b>1</b> <sup>b</sup>     | MeCN    | 5         | 18 W 455 nm        | 48        | 25 (4 : 1)                                       |
| 2         | [Ir] <b>1</b> <sup>b</sup>     | DMF     | 5         | 18 W 455 nm        | 48        | 42 (4 : 1)                                       |
| 3         | [Ir] <b>1</b> <sup>b</sup>     | DCE     | 5         | 18 W 455 nm        | 48        | 43 (4 : 1)                                       |
| 4         | [Ir] <b>1</b> <sup>b</sup>     | DMA     | 5         | 18 W 455 nm        | 48        | 36 (4 : 1)                                       |
| 5         | [Ir] <b>2</b> <sup>b</sup>     | DMA     | 5         | 18 W 455 nm        | 48        | 15 (4 : 1)                                       |
| 6         | [Ir] <b>3</b> <sup>b</sup>     | DMA     | 5         | 18 W 455 nm        | 48        | 35 (4 : 1)                                       |
| 7         | <b>4CzIPN</b> <sup>c</sup>     | DMA     | 5         | 18 W 455 nm        | 48        | 45 (4 : 1)                                       |
| 8         | <b>4CzIPN</b> <sup>c</sup>     | DMA     | 10        | 18 W 455 nm        | 48        | 60 (6 : 1)                                       |
| 9         | <b>4CzIPN</b> <sup>c</sup>     | DMA     | 10        | 30 W 440 nm        | 24        | 65 (6 : 1)                                       |
| <b>10</b> | <b>4CzIPN</b> <sup>c,d</sup>   | DMA     | <b>10</b> | <b>30 W 440 nm</b> | <b>24</b> | <b>70 (6 : 1)</b>                                |
| 11        | <b>4CzIPN</b> <sup>c,d,e</sup> | DMA     | 10        | 30 W 440 nm        | 24        | 62 (6 : 1)                                       |
| 12        | <b>4CzIPN</b> <sup>c,d</sup>   | DMA     | 10        | None               | 24        | <5   |
| 13        | None <sup>d</sup>              | DMA     | 10        | 30 W 440 nm        | 24        | 20 (6 : 1)                                       |

<sup>a</sup> Yield determined by <sup>1</sup>H NMR spectroscopy using trimethoxybenzene as internal standard. <sup>b</sup> 1 mol% of catalyst. <sup>c</sup> 2.5 mol% of catalyst. <sup>d</sup> 10 equiv. of water added. <sup>e</sup> Under air. PC = photocatalyst.






**Scheme 1** Substrate scope for  $\alpha$ -amino bicyclo[1.1.1]pentylation reaction; isolated yields shown. <sup>a</sup> Isolated as a 6 : 1 mixture with **5**, <sup>b</sup> isolated as a 5 : 1 mixture with **5**, <sup>c</sup> isolated as a 12 : 1 mixture with **5**, <sup>d</sup> isolated as a 4 : 1 mixture with **5**; <sup>e</sup> isolated as a 10 : 1 mixture with **5**; <sup>f</sup> isolated as a 3 : 1 mixture with **5**.

24% yield, along with 6% of the 'staffane' product **5a**, which results from addition of the initially formed BCP radical to another molecule of **1** (Table 1, entry 1). A solvent screen revealed that DMF, DCE and DMA gave improved yields of **4a** (36–43%, entries 2–4). Various other oxidising iridium and organophotocatalysts were investigated; while the use of  $[\text{Ir}]_2 E^\circ(\text{Ir(III)}^*/\text{Ir(II)}) = +1.32 \text{ V vs. SCE}$ <sup>59</sup> or  $[\text{Ir}]_3$  led to decreased yields (entries 5 and 6), the organophotocatalyst **4CzIPN** ( $E^\circ = 1.35 \text{ V vs. SCE}$ )<sup>60</sup> afforded **4a** in 45% yield with 11% of **5a** (entry 7). Additives including a range of H-atom sources and bases were not beneficial (see the ESI, Table S1†), but pleasingly an enhanced yield of product (60%, entry 8) and ratio of **4a** : **5a** (6 : 1) could be obtained by increasing the stoichiometry of aniline **3a** to 10 equiv. Changing to a stronger light source (30 W, 440 nm) further increased the yield of **4a** and permitted a shorter reaction time (65%, entry 9). The addition of 10 equiv. of water

marginally increased the yield of the desired product to 70% (entry 10). Conducting the reaction under an atmosphere of air resulted in slightly reduced yields (entry 11), while control experiments demonstrated that both photocatalyst and light were required to afford high yields of **4a** (entries 12 and 13). We found that, if desired, unreacted amine **3a** could be recovered in near quantitative yield *via* chromatographic purification.

With optimised conditions in hand, the scope of the aniline coupling partner was investigated, focussing first on variation of the *N*-arene substituent. We found this method of BCP installation to be successful with diversely functionalised (hetero)arylpiperidine substrates, with the  $\alpha$ -amino BCP products generally obtained in good yields (Scheme 1). Electron-neutral and electron-poor *para*-substituted aniline substrates are well-suited to this reaction and gave good-to-excellent yields of the desired  $\alpha$ -amino BCP products (**4a–f**, 52–80%).





Scheme 2 Bicyclopentylation of nicotine (**6**, 10 equiv.); **7** was isolated as a 4 : 1 mixture with the corresponding BCP-staffane.

Substitution at the *meta*- and *ortho*-positions was also tolerated (**4g–h**, 35–46%), as were trisubstituted anilines (**4i**, 60%). The synthesis of BCPs substituted with heteroaryl dialkylanilines would be of high interest in a pharmaceutical context; pleasingly, we found that 2-, 3-, and 4-pyrrolidinopyridines were excellent substrates for this reaction, affording BCP products in high yields (**4j–l**, 63–70%); similarly a pyrrolidine–quinoline derivatives gave the BCP product **4m** in good yield (61%).

We next investigated substrates in which the dialkylamine was varied. Pleasingly, piperidine (**4n**, 52%), azepane (**4o–p**, 43–47%) and morpholine (**4q**, 40%) substituted (hetero)arene BCPs were isolated in good yields, albeit with a slight increase in the amount of staffane side-product. Substrates bearing substituted pyrrolidines proved more challenging: while hexahydrocyclopenta[*c*]pyrrole **4q** was obtained in excellent yield (71%), the use of non-symmetric substrates resulted in mixtures of product regioisomers, although high yields were still obtained (e.g. **4r** and **4s**, 61%). For reasons that are unclear, acyclic dialkylamine systems generally resulted in low yields, with significant amounts of staffane formation (**4u**, 23%).

Recent studies suggest that nicotine may exert neuro-protective effects inducing defence mechanisms against pathologies associated with Alzheimer's or Parkinson's disease.<sup>19–28</sup> Pleasingly, use of nicotine (**6**, Scheme 2) as a substrate for this  $\alpha$ -aminobicyclopentylation reaction led to the corresponding BCP–nicotine derivative **7** (37%), highlighting the applicability of the chemistry to drug molecules. C–H abstraction occurs preferentially at the 2° position adjacent to the nitrogen atom due to the stability of the resulting  $\alpha$ -amino radical.<sup>61</sup> While a 3° radical at the opposing  $\alpha$ -position should be significantly more stable than any of the 1° or 2°

radicals that could be formed, we suggest that steric repulsion encountered during the C–H abstraction process prevents the formation of this radical, rationalising the observed regioselectivity of the reaction.


Considering the excellent results obtained in the bicyclopentylation reactions of **1** to form  $\alpha$ -amino BCPs, and the high relevance of recently discovered BCHePs as potential bioisosteres of *meta*-substituted arenes,<sup>13</sup> we questioned whether [3.1.1]propellane **2** would also perform well in this nucleophilic radical addition chemistry. We first studied the stability of **2** under blue LED irradiation (440 nm), which confirmed that **2** is stable for several hours.<sup>61</sup> Under the optimised conditions developed for the bicyclopentylation, we explored the reaction of **2** with aniline **3a**. The use of 1 equiv. of amine **3a** under the optimized reaction conditions afforded the desired product **8a** in low yield (18%, Table 2, entry 1), as a 4 : 1 mixture with the corresponding BCHeP staffane **9a** (which notably constitutes the first example of this type of 'dimer' formation for [3.1.1]propellane).<sup>13</sup> An increase in yield but a similar product-staffane ratio was observed using 5 equiv. of amine **3a** (47% (4 : 1), entry 2), while the use of 10 equiv. of amine resulted in enhancement of both the yield and product : staffane ratio (82% (5 : 1), entry 3).

These conditions were applied to a range of amine substrates (Scheme 3). We observed that anilines featuring neutral and electron-withdrawing *N*-aryl groups were well-tolerated, affording the corresponding  $\alpha$ -amino BCHePs in good to excellent yields (**8a–c**, 52–82%), while more electron-deficient *N*-aryls (*para*-fluorine or *meta*-cyano substitution) led to low yields of BCHeP product (**8d–e**, 20–21%). Notably, the replacement of the *N*-aryl and pyrrolidine rings with pyridine or morpholine motifs respectively was successful, generating BCHePs that feature

Table 2 Optimisation of the addition of  $\alpha$ -amino radicals to [3.1.1]propellane<sup>a</sup>

| Entry | Amine equiv. | Time (h) | Isolated Yield ( <b>8a</b> : <b>9a</b> ) <sup>a</sup> |
|-------|--------------|----------|---|
| 1     | 1            | 16       | 18% (4 : 1)   |
| 2     | 5            | 16       | 47% (4 : 1)   |
| 3     | 10           | 16       | 82% (5 : 1)   |

<sup>a</sup> Reactions conducted using **2** (1 equiv.), **3a** (10 equiv.) at room temperature.



Scheme 3 Substrate scope for  $\alpha$ -amino bicyclo[3.1.1]heptane reaction; isolated yields shown. <sup>a</sup> Isolated as a 5 : 1 mixture with **9a** (from **8a**) or **9d** (from **8d**). <sup>b</sup> Isolated as a 10 : 1 mixture with **9f**.





multiple ‘drug-like’ functionalities (**8f–g**, 43–56%). Interestingly, only phenyl, *para*-fluorophenyl and pyridine corresponding BCHeP staffanes (**9a**, **9d**, **9f**); staffane formation was not observed for other substrates.

### Mechanistic studies

A mechanistic cycle is proposed in Fig. 2a. Initial excitation of the photocatalyst gives a highly oxidising species ( $E^\circ = 1.35$  V vs. SCE)<sup>62</sup> which is capable of oxidising the amine ( $E_{\text{calc}}^\circ = +0.74 - 0.88$  V vs. SCE),<sup>63</sup> followed by deprotonation of the resulting radical cation **10** (by excess **3a**) to form an  $\alpha$ -

amino radical **11**. This proposal is supported by a Stern–Volmer quenching study in which the amine **3a** quenches the luminescence of the photocatalyst with >40 times the efficiency of **1** (Fig. 2b). The resulting  $\alpha$ -amino radical can add to the inter-bridgehead bond of [1.1.1]propellane to form a bridgehead BCP radical **12**, which can then either abstract an H atom from the  $\alpha$ -position of a second molecule of the amine (to propagate a chain process), or from radical cation **10**, or from the solvent; these HAT processes are in competition with staffane formation. Catalyst turnover can then be achieved by reduction of iminium ion **14**. An alternative fate for the BCP radical could be reduction by the reduced photocatalyst ( $E^\circ = -1.21$  V vs. SCE)<sup>62</sup> to complete the catalytic cycle, followed by quenching of the BCP anion by water present in the reaction; however, calculations suggest that reduction of BCP radical by the **4CzIPN** radical anion would be an approximately thermoneutral process ( $\Delta E_{\text{calc}} = 0.17$  V, Fig. 2c) and may therefore be outcompeted by alternative low-barrier processes such as HAT. Further calculations (Fig. 2d) identified transition state barriers for hydrogen-atom transfer to a methyl-substituted BCP radical **15** with *N*-phenylpyrrolidine (**3a**) ( $\Delta G^\ddagger = 13.1$  kcal mol<sup>-1</sup>), Et<sub>2</sub>O ( $\Delta G^\ddagger = 14.8$  kcal mol<sup>-1</sup>) and DMA ( $\Delta G^\ddagger = 15.4$  kcal mol<sup>-1</sup>) at potential hydrogen atom sources.<sup>64</sup> The lower barrier of the former of these (**3a**) can be attributed to the greater stability of the developing  $\alpha$ -amino radical over the corresponding Et<sub>2</sub>O/DMA radicals. The importance of this radical stability is shown by the use of dimethylaniline **3u** as the HAT source: its 1°  $\alpha$ -amino radical is 1.0 kcal mol<sup>-1</sup> less stable than the 2° radical derived from **3a**, and the barrier to HAT increases to 14.5 kcal mol<sup>-1</sup>. The radical chain process is then in closer competition with HAT from the solvent ( $\Delta\Delta G^\ddagger = 0.3$  kcal mol<sup>-1</sup>), which we hypothesise could decrease the radical chain length, and may be the cause of the poorer yield (of **4u**, 23%), and product : staffane ratio (3 : 1), observed for this substrate.

The preference for HAT transfer from **3a**, rather than the solvent or H<sub>2</sub>O, was further explored using deuterium-labelling studies (Table 3). We first confirmed that under the standard conditions, no deuterium incorporation was observed in the presence of D<sub>2</sub>O, ruling out the reduction of the BCP radical as a catalyst turnover step (entry 2). Use of d<sub>7</sub>-DMF (as a surrogate for DMA) also led to no product deuteration (entry 3). However, 80% D-incorporation was observed using d<sub>4</sub>-*N*-phenylpyrrolidine (entry 4, **d<sub>4</sub>-3a**), albeit this reaction proceeded in very low yield. A significantly greater amount of staffane was observed, which is consistent with the slower rate of deuterium atom transfer compared to HAT with **h<sub>4</sub>-3a** (**4a** : **5a** = 1.3 : 1 vs. 6.4 : 1). Only 34% D-incorporation was observed when using d<sub>4</sub>-*N*-phenylpyrrolidine in combination with a DMA/Et<sub>2</sub>O solvent mixture (entry 5), suggesting that these solvents may also act as H-atom sources in the presence of deuterated substrate.

Equivalent deuteration studies were next performed using [31.1]propellane **2** as acceptor, which confirmed that the substrate **3a** is again a capable H atom donor, with 38% D-incorporation using d<sub>4</sub>-*N*-phenylpyrrolidine, DMA and H<sub>2</sub>O (entries 7 and 8). However, additional experiments revealed that in the case of **2**, use of D<sub>2</sub>O resulted in a surprising 21% D-incorporation and a much superior yield (entry 9).





Fig. 2 (a) Proposed mechanistic cycle for the formation of  $\alpha$ -amino BCPs from amines and [1.1.1]propellane **1** ( $n = 1$ ) or [3.1.1]propellane **2** ( $n = 3$ ). (b) Stern–Volmer quenching plot for amine **3a** and [1.1.1]propellane **1** with **4CzIPN**. (c) Calculated  $E^\circ$  values (V vs. SCE) for **3a**, **12** and **14**. (d) Calculated H-atom transfer barriers using amines **3a**, **3u**, DMA, and Et<sub>2</sub>O.<sup>64</sup> Free energies were calculated at 298.15 K, and the standard concentration of each species was adjusted for the experimental molar ratios (**3a**/**3u**: 10.0 equiv., DMA: 21.6 equiv., Et<sub>2</sub>O: 12.0 equiv.).



Table 3 Deuterium-labelling studies



| Entry           | Substrates             | Solvent                                 | Additive         | % D | Yield (%)<br>(4a : 5a)/(8a : 9a) |
|-----------------|------------------------|---|------------------|-----|----------------------------------|
| 1               | 1 + h <sub>4</sub> -3a | DMA/Et <sub>2</sub> O                   | H <sub>2</sub> O | 0   | 70 (6.4 : 1)                     |
| 2               | 1 + h <sub>4</sub> -3a | DMA/Et <sub>2</sub> O                   | D <sub>2</sub> O | 0   | 70 (6.4 : 1)                     |
| 3               | 1 + h <sub>4</sub> -3a | d <sub>7</sub> -DMF/pentane             | D <sub>2</sub> O | 0   | 70 (6.4 : 1)                     |
| 4 <sup>a</sup>  | 1 + d <sub>4</sub> -3a | d <sub>7</sub> -DMF/pentane             | D <sub>2</sub> O | 80  | 7 (1.3 : 1)                      |
| 5 <sup>a</sup>  | 1 + d <sub>4</sub> -3a | DMA/Et <sub>2</sub> O                   | D <sub>2</sub> O | 34  | 10 (1.6 : 1)                     |
| 6 <sup>a</sup>  | 1 + d <sub>4</sub> -3a | d <sub>7</sub> -DMF/Et <sub>2</sub> O   | D <sub>2</sub> O | 63  | 10 (1.5 : 1)                     |
| 7               | 2 + h <sub>4</sub> -3a | DMA/n-Bu <sub>2</sub> O                 | H <sub>2</sub> O | 0   | 82 (5 : 1)                       |
| 8 <sup>a</sup>  | 2 + d <sub>4</sub> -3a | DMA/n-Bu <sub>2</sub> O                 | H <sub>2</sub> O | 38  | 19 (3.5 : 1)                     |
| 9               | 2 + h <sub>4</sub> -3a | DMA/n-Bu <sub>2</sub> O                 | D <sub>2</sub> O | 21  | 79 (5 : 1)                       |
| 10 <sup>a</sup> | 2 + d <sub>4</sub> -3a | DMA/n-Bu <sub>2</sub> O                 | D <sub>2</sub> O | 49  | 10 (3.5 : 1)                     |
| 11 <sup>a</sup> | 2 + d <sub>4</sub> -3a | d <sub>7</sub> -DMF/n-Bu <sub>2</sub> O | D <sub>2</sub> O | 74  | 8 (2 : 1)                        |

<sup>a</sup> d<sub>4</sub>-3a = 98% D.

Furthermore, 49% deuteration was observed using a combination of d<sub>4</sub>-3a and D<sub>2</sub>O (entry 10), and the introduction of d<sub>7</sub>-DMF further increased the extent of deuteration to 74%, confirming the participation of multiple H-atom sources, including the solvent (entry 11). The BCHeP/staffane ratios gradually decreased from 5 : 1 (entries 7 and 8), progressing to 3.5 : 1 (entries 9 and 10), and finally reaching 2 : 1 (entry 11), showing that the bicycloheptylation reaction also features a fine balance between HAT and staffane formation.

Additional evidence for our mechanistic proposal was obtained using the kinetic isotope effect (KIE) observed for the HAT step in the reactions of **1**. Since staffane formation is independent of the deuteration state of the amine, the product:staffane ratio for h<sub>4</sub>- and d<sub>4</sub>-N-phenylpyrrolidines (Table 3, entries 1 vs. 4) should approximate the HAT KIE, *i.e.*  $k_{\text{H}}/k_{\text{D}} \approx (4\mathbf{a} : 5\mathbf{a})/(\mathbf{d}\mathbf{4}\mathbf{a} : \mathbf{d}\mathbf{5}\mathbf{a})$  (see ESI† for further discussion). Using this approach, a KIE of  $4.9 \pm 0.5$  was obtained, which is in reasonable agreement with the value obtained from computation ( $k_{\text{H}}/k_{\text{D}} = 6.1$ ).


While a chain process is evidently possible, the low quantum yield of 0.84 obtained for this reaction suggests catalyst turnover is important.<sup>61</sup> Since reduction of the BCP radical is not

viable to achieve turnover (at least for [1.1.1]propellane, as evidenced by the lack of deuteration of **4a** in the presence D<sub>2</sub>O for this propellane), it may be that a fast HAT process between BCP radical **12** and low-concentration radical cation **10** could occur that would lead to the formation of iminium ion **14**. This iminium ion could then be reduced by 4CzIPN<sup>-</sup> to reform the neutral organophotoredox catalyst, and an  $\alpha$ -amino radical **11** ( $\Delta E_{\text{calc}} = +0.88$  V).

Finally, the successful use of different propellanes in this aminobicycloalkylation offers the opportunity to compare the relative propensity of the two to undergo ring-opening. A competition experiment was therefore undertaken in which the reaction was conducted using an equimolar mixture of **1** and **2**; this experiment revealed that the formation of BCP derivative **4e** is  $\sim 3.9$  times faster than BCHeP product **8d** as judged by NMR monitoring of the proportions of products formed during the reaction.<sup>61</sup> This reveals an enhanced reactivity of [1.1.1]propellane **1** compared to [3.1.1]propellane **2**, at least in this particular setting of nucleophilic radical addition chemistry (Scheme 4).

## Conclusions

In conclusion, we have developed an organocatalysed photoredox approach for the synthesis of  $\alpha$ -amino BCPs and BCHePs through the addition of  $\alpha$ -amino radicals to the strained interbridgehead of [1.1.1] and [3.1.1]propellanes respectively. The reaction displays scope that is of high relevance in medicinal chemistry research, where such motifs are of high importance. A combination of experimental and computational mechanistic studies provide evidence for a radical chain pathway, and also



Scheme 4 Competition experiment: [1.1.1]propellane **1** vs. [3.1.1]propellane **2**.



offer insight into the kinetics of hydrogen atom transfer steps of bridgehead bicycloalkyl radicals.

## Data availability

The datasets supporting this article have been uploaded as part of the ESI.†

## Author contributions

J. N. and E. A. conceived the project. J. N., A. L.-F., A. J. S., M. Y.-T. carried out the experimental work. A. J. S. and N. F. carried out the computational work. J. N., J. J. M., F. D. and E. A. directed the project. J. N., A. L.-F., A. J. S. and E. A. wrote the manuscript. All authors contributed to editing and revision of the manuscript.

## Conflicts of interest

There are no conflicts to declare.

## Acknowledgements

J. N. thanks the Marie Skłodowska-Curie actions for an Individual Fellowship (GA No. 786683). A. J. S. thanks the EPSRC Centre for Doctoral Training in Synthesis for Biology and Medicine for studentships (EP/L015838/1), generously supported by AstraZeneca, Diamond Light Source, Defence Science and Technology Laboratory, Evotec, GlaxoSmithKline, Janssen, Novartis, Pfizer, Syngenta, Takeda, UCB and Vertex. A. L.-F. thanks the Basque Government for a Predoctoral (PRE\_2022\_2\_0112) and Egonlabur (EP\_2023\_1\_0047) fellowships. E. A. A. thanks the EPSRC for support (EP/S013172/1). A. J. S. and F. D. thank the EPSRC Tier-2 National HPC Facility Service (<https://www.cirrus.ac.uk>), and the EPSRC Centre for Doctoral Training for Theory and Modelling in Chemical Sciences (No. EP/L015722/1) for providing access to the Dirac Cluster at Oxford.

## Notes and references

- M. R. Bauer, P. Di Fruscia, S. C. C. Lucas, I. N. Michaelides, J. E. Nelson, R. I. Storer and B. C. Whitehurst, *RSC Med. Chem.*, 2021, **12**, 448–471.
- G. M. Locke, S. S. R. Bernhard and M. O. Senge, *Chem.–Eur. J.*, 2019, **25**, 4590–4647.
- M. A. M. Subbaiah and N. A. Meanwell, *J. Med. Chem.*, 2021, **64**, 14046–14128.
- N. A. Meanwell, *Chem. Res. Toxicol.*, 2016, **29**, 564–616.
- P. K. Mykhailiuk, *Org. Biomol. Chem.*, 2019, **17**, 2839–2849.
- N. A. Meanwell, *J. Agric. Food Chem.*, 2023, **71**, 18087–18122.
- F. Lovering, J. Bikker and C. Humblet, *J. Med. Chem.*, 2009, **52**, 6752–6756.
- Y. P. Auberson, C. Brocklehurst, M. Furegati, T. C. Fessard, G. Koch, A. Decker, L. La Vecchia and E. Briard, *ChemMedChem*, 2017, **12**, 590–598.
- A. F. Stepan, C. Subramanyam, I. V. Efremov, J. K. Dutra, T. J. O'Sullivan, K. J. DiRico, W. S. McDonald, A. Won, P. H. Dorff, C. E. Nolan, S. L. Becker, L. R. Pustilnik, D. R. Riddell, G. W. Kauffman, B. L. Kormos, L. Zhang, Y. Lu, S. H. Capetta, M. E. Green, K. Karki, E. Sibley, K. P. Atchison, A. J. Hallgren, C. E. Oborski, A. E. Robshaw, B. Sneed and C. J. O'Donnell, *J. Med. Chem.*, 2012, **55**, 3414–3424.
- N. D. Measom, K. D. Down, D. J. Hirst, C. Jamieson, E. S. Manas, V. K. Patel and D. O. Somers, *ACS Med. Chem. Lett.*, 2017, **8**, 43–48.
- Y. L. Goh, Y. T. Cui, V. Pendharkar and V. A. Adsool, *ACS Med. Chem. Lett.*, 2017, **8**, 516–520.
- I. S. Makarov, C. E. Brocklehurst, K. Karaghiosoff, G. Koch and P. Knochel, *Angew. Chem., Int. Ed.*, 2017, **56**, 12774–12777.
- S. J. Nara, S. Jogi, S. Cheruku, S. Kandhasamy, F. Jaipuri, P. K. Kathi, S. Reddy, S. Sarodaya, E. M. Cook, T. Wang, D. Sitkoff, K. A. Rossi, M. Ruzanov, S. E. Kiefer, J. A. Khan, M. Gao, S. Reddy, S. Sivaprasad Lvj, R. Sane, K. Mosure, X. Zhuo, G. G. Cao, M. Ziegler, A. Azzara, J. Krupinski, M. G. Soars, B. A. Ellsworth and D. A. Wacker, *J. Med. Chem.*, 2022, **65**, 8948–8960.
- B. Owen, M. de Gaetano, A. Gaffney, C. Godson and P. J. Guiry, *Org. Lett.*, 2022, **24**, 6049–6053.
- J. Weinmann, L. Kirchner, M. Engstler, L. Meinel and U. Holzgrabe, *Eur. J. Med. Chem.*, 2023, **250**, 115176.
- R. J. Altenbach, A. Bogdan, S. Couty, E. De Lemos, N. Desroy, B. Duthion, G. A. Gfesser, S. N. Greszler, C. G. Housseman, J. R. Koenig, P. R. Kym, B. Liu, M. J. Scanio, X. Searle, X. Wang, M. C. Yeung and G. Zhao, WO2018065962A1, 2018.
- M. V. Westphal, B. T. Wolfstädter, J.-M. Plancher, J. Gatfield and E. M. Carreira, *ChemMedChem*, 2015, **10**, 461–469.
- N. Frank, J. Nugent, B. R. Shire, H. D. Pickford, P. Rabe, A. J. Sterling, T. Zarganes-Tzitzikas, T. Grimes, A. L. Thompson, R. C. Smith, C. J. Schofield, P. E. Brennan, F. Duarte and E. A. Anderson, *Nature*, 2022, **611**, 721–726.
- X. Zhang, R. T. Smith, C. Le, S. J. McCarver, B. T. Shireman, N. I. Carruthers and D. W. C. MacMillan, *Nature*, 2020, **580**, 220–226.
- P. Kaszynski, A. C. Friedli and J. Michl, *J. Am. Chem. Soc.*, 1992, **114**, 601–620.
- J. Kanazawa, K. Maeda and M. Uchiyama, *J. Am. Chem. Soc.*, 2017, **139**, 17791–17794.
- M. Kondo, J. Kanazawa, T. Ichikawa, T. Shimokawa, Y. Nagashima, K. Miyamoto and M. Uchiyama, *Angew. Chem., Int. Ed.*, 2020, **59**, 1970–1974.
- J. Nugent, C. Arroniz, B. R. Shire, A. J. Sterling, H. D. Pickford, M. L. J. Wong, S. J. Mansfield, D. F. J. Caputo, B. Owen, J. J. Mousseau, F. Duarte and E. A. Anderson, *ACS Catal.*, 2019, **9**, 9568–9574.
- M. L. J. Wong, J. J. Mousseau, S. J. Mansfield and E. A. Anderson, *Org. Lett.*, 2019, **21**, 2408–2411.
- J. H. Kim, A. Ruffoni, Y. S. S. Al-Faiyz, N. S. Sheikh and D. Leonori, *Angew. Chem., Int. Ed.*, 2020, **59**, 8225–8231.
- D. F. J. Caputo, C. Arroniz, A. B. Dürr, J. J. Mousseau, A. F. Stepan, S. J. Mansfield and E. A. Anderson, *Chem. Sci.*, 2018, **9**, 5295–5300.



- 27 R. M. Bär, S. Kirschner, M. Nieger and S. Bräse, *Chem.–Eur. J.*, 2018, **24**, 1373–1382.
- 28 H. D. Pickford, J. Nugent, B. Owen, J. J. Mousseau, R. C. Smith and E. A. Anderson, *J. Am. Chem. Soc.*, 2021, **143**, 9729–9736.
- 29 W. Huang, Y. Zheng, S. Keess and G. A. Molander, *J. Am. Chem. Soc.*, 2023, **145**, 5363–5369.
- 30 Y. Guo, J. Zhu, Y. Wang, Y. Li, H. Hu, P. Zhang, J. Xu and W. Li, *ACS Catal.*, 2024, **14**, 619–627.
- 31 H. D. Pickford, V. Ripenko, R. E. McNamee, S. Holovchuk, A. L. Thompson, R. C. Smith, P. K. Mykhailiuk and E. A. Anderson, *Angew. Chem., Int. Ed.*, 2023, **62**, e202213508.
- 32 J. Nugent, A. J. Sterling, N. Frank, J. J. Mousseau and E. A. Anderson, *Org. Lett.*, 2021, **23**, 8628–8633.
- 33 M. Messner, S. I. Kozhushkov and A. de Meijere, *Eur. J. Org. Chem.*, 2000, 1137–1155.
- 34 R. Gianatassio, J. M. Lopchuk, J. Wang, C.-M. Pan, L. R. Malins, L. Prieto, T. A. Brandt, M. R. Collins, G. M. Gallego, N. W. Sach, J. E. Spangler, H. Zhu, J. Zhu and P. S. Baran, *Science*, 2016, **351**, 241–246.
- 35 J. M. Lopchuk, K. Fjelbye, Y. Kawamata, L. R. Malins, C.-M. Pan, R. Gianatassio, J. Wang, L. Prieto, J. Bradow, T. A. Brandt, M. R. Collins, J. Elleraas, J. Ewanicki, W. Farrell, O. O. Fadeyi, G. M. Gallego, J. J. Mousseau, R. Oliver, N. W. Sach, J. K. Smith, J. E. Spangler, H. Zhu, J. Zhu and P. S. Baran, *J. Am. Chem. Soc.*, 2017, **139**, 3209–3226.
- 36 N. Trongsirawat, Y. Pu, Y. Nieves-Quinones, R. A. Shelp, M. C. Kozłowski and P. J. Walsh, *Angew. Chem., Int. Ed.*, 2019, **58**, 13416–13420.
- 37 R. A. Shelp and P. J. Walsh, *Angew. Chem., Int. Ed.*, 2018, **57**, 15857–15861.
- 38 R. A. Shelp, A. Ciro, Y. Pu, R. R. Merchant, J. M. E. Hughes and P. J. Walsh, *Chem. Sci.*, 2021, **12**, 7066–7072.
- 39 K. Schwärzer, H. Zipse, K. Karaghiosoff and P. Knochel, *Angew. Chem., Int. Ed.*, 2020, **59**, 20235–20241.
- 40 Approved pharmaceuticals featuring a benzylamine motif include benzphetamine, bethanidine, buclizine, meclizine, terbinafine and ticlopidine.
- 41 S. Pritz, M. Pätzelt, G. Szeimies, M. Dathe and M. Bienert, *Org. Biomol. Chem.*, 2007, **5**, 1789–1794.
- 42 S. Ni, A. F. Garrido-Castro, R. R. Merchant, J. N. de Gruyter, D. C. Schmitt, J. J. Mousseau, G. M. Gallego, S. Yang, M. R. Collins, J. X. Qiao, K.-S. Yeung, D. R. Langley, M. A. Poss, P. M. Scola, T. Qin and P. S. Baran, *Angew. Chem., Int. Ed.*, 2018, **57**, 14560–14565.
- 43 S. O. Kokhan, A. V. Tymtsunik, S. L. Grage, S. Afonin, O. Babii, M. Berditsch, A. V. Strizhak, D. Bandak, M. O. Platonov, I. V. Komarov, A. S. Ulrich and P. K. Mykhailiuk, *Angew. Chem., Int. Ed.*, 2016, **55**, 14788–14792.
- 44 R. A. Shelp, A. Ciro, Y. Pu, R. R. Merchant, J. M. E. Hughes and P. J. Walsh, *Chem. Sci.*, 2021, **12**, 7066–7072.
- 45 A. J. Sterling, A. B. Dürr, R. C. Smith, E. A. Anderson and F. Duarte, *Chem. Sci.*, 2020, **11**, 4895–4903.
- 46 M. L. J. Wong, A. J. Sterling, J. J. Mousseau, F. Duarte and E. A. Anderson, *Nat. Commun.*, 2021, **12**, 1644.
- 47 K. B. Wiberg and S. T. Waddell, *J. Am. Chem. Soc.*, 1990, **112**, 2194–2216.
- 48 D. T. Ahneman and A. G. Doyle, *Chem. Sci.*, 2016, **7**, 7002–7006.
- 49 Y.-Y. Gui, L.-L. Liao, L. Sun, Z. Zhang, J.-H. Ye, G. Shen, Z.-P. Lu, W.-J. Zhou and D.-G. Yu, *Chem. Commun.*, 2017, **53**, 1192–1195.
- 50 Y.-Y. Gui, Z.-X. Wang, W.-J. Zhou, L.-L. Liao, L. Song, Z.-B. Yin, J. Li and D.-G. Yu, *Asian J. Org. Chem.*, 2018, **7**, 537–541.
- 51 X. Si, L. Zhang and A. S. K. Hashmi, *Org. Lett.*, 2019, **21**, 6329–6332.
- 52 C. Bosset, H. Beucher, G. Bretel, E. Pasquier, L. Queguiner, C. Henry, A. Vos, J. P. Edwards, L. Meerpoel and D. Berthelot, *Org. Lett.*, 2018, **20**, 6003–6006.
- 53 J. B. McManus, N. P. R. Onuska and D. A. Nicewicz, *J. Am. Chem. Soc.*, 2018, **140**, 9056–9060.
- 54 L. Ruiz Espelt, E. M. Wiensch and T. P. Yoon, *J. Org. Chem.*, 2013, **78**, 4107–4114.
- 55 R. A. Aycock, C. J. Pratt and N. T. Jui, *ACS Catal.*, 2018, **8**, 9115–9119.
- 56 P. Kohls, D. Jadhav, G. Pandey and O. Reiser, *Org. Lett.*, 2012, **14**, 672–675.
- 57 C. J. Pratt, R. A. Aycock, M. D. King and N. T. Jui, *Synlett*, 2020, **31**, 51–54.
- 58 Y. He, Z. Zheng, J. Yang, X. Zhang and X. Fan, *Org. Chem. Front.*, 2021, **8**, 4582–4606.
- 59 G. Duret, R. Quinlan, P. Bissere and N. Blanchard, *Chem. Sci.*, 2015, **6**, 5366–5382.
- 60 M. A. Bryden and E. Zysman-Colman, *Chem. Soc. Rev.*, 2021, **50**, 7587–7680.
- 61 See the ESI† for details.
- 62 T.-Y. Shang, L.-H. Lu, Z. Cao, Y. Liu, W.-M. He and B. Yu, *Chem. Commun.*, 2019, **55**, 5408–5419.
- 63 H. G. Roth, N. A. Romero and D. A. Nicewicz, *Synlett*, 2016, **27**, 714–723.
- 64 T. A. Young, J. J. Silcock, A. J. Sterling and F. Duarte, *Angew. Chem., Int. Ed.*, 2021, **60**, 4266–4274.

